MLEC (MLEC) Stock Price & Analysis
MLEC (MLEC) rose 0.42% to USD 7.17 as of June 10, 2026 at 07:13 UTC, according to Nexqual real-time market data.
MLEC last closed at USD 7.14; the session ranged USD 7.05–7.35 on volume of 8,807 shares. Market capitalization is $5.21M, with a 52-week range of USD 3.08–120 (NCM). Source: Nexqual, June 10, 2026 at 07:13 UTC.
Key Statistics (as of June 10, 2026 at 07:13 UTC)
| Price | USD 7.17 |
|---|---|
| Change | ▲ 0.42% (up) |
| Previous Close | USD 7.14 |
| Open | USD 7.35 |
| Day Range | USD 7.05 – 7.35 |
| 52-Week Range | USD 3.08 – 120 |
| Volume | 8,807 shares |
| Market Cap | $5.21M |
| Exchange | NCM |
Technical Analysis (MLEC)
Nexqual's technical model rates MLEC "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:13 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.85 (neutral) |
| vs SMA50 | Below (USD 8.05) |
| MACD | -0.28 (negative) |
Analyst Ratings (MLEC)
Wall Street analysts rate MLEC "None", per Nexqual as of June 10, 2026 at 07:13 UTC.
| Consensus Rating | None |
|---|
Earnings (MLEC)
Source: Nexqual, June 10, 2026 at 07:13 UTC.
Financials & Fundamentals (MLEC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
Source: Nexqual, June 10, 2026 at 07:13 UTC.
Financial Health Score (MLEC)
Nexqual rates MLEC's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:13 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (MLEC)
| Insider Ownership | +21.06% |
|---|---|
| Institutional Ownership | +2.28% |
| Shares Outstanding | 726,118 |
| Short % of Float | +1.58% |
Source: Nexqual, June 10, 2026 at 07:13 UTC.
Leadership (MLEC)
MLEC is led by Alejandro Antalich (age 51), Chief Executive Officer, per Nexqual as of June 10, 2026 at 07:13 UTC.
| Chief Executive Officer | Alejandro Antalich (age 51) |
|---|---|
| Co-Founder & Chief Product Officer | Henk Hoogenkamp (age 37) |
| Chief Financial Officer | Valeria Falottico (age 43) |
| Chief Technology Officer | Paola Díaz Dellavalle (age 49) |
Major Backers & Investors (MLEC)
Notable institutional backers of MLEC include HRT Financial LP, according to Nexqual as of June 10, 2026 at 07:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HRT Financial LP | 2.28% |
Source: Nexqual, June 10, 2026 at 07:13 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.94 | ▼ 1.02% |
| ATPC | Agape ATP Corporation | USD 3.12 | ▲ 4.7% |
| CMND | Clearmind Medicine Inc. | USD 3.39 | ▼ 14.82% |
| AIMD | Ainos, Inc. | USD 2.04 | ▲ 4.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:13 UTC. This page is informational and not investment advice.